Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial is to determine an effective dosage and to study the safety of an investigational drug -lidorestat (IDD-676)- which is intended to stop or slow the progression of diabetic peripheral neuropathy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Institute for Diabetes Discovery, LLC

Criteria

Inclusion:

• Clinical diagnosis of Type 1 or Type II diabetes with mild to moderate diabetic peripheral neuropathy.

• Healthy status except for diabetes

• Ability to make frequent clinic visits over a 7-month period.

• Willingness and ability to understand and sign consent form.

Exclusion:

• Pregnancy or breast feeding

• Presence of uncontrolled hypertension

• History or presence of significant kidney or liver disease.